What is Keryx's burn rate, and how much cash does it have on hand?
Steve Jobs certainly didn't need to do more. He accomplished more than most could ever dream of. However, there is another way he could have done even more good at almost no cost to him.
Cancer research is big business, and it pays to know where research dollars are headed.
A Fool bets real money in a three-year tussle with Mr. Market.
And will begin answering to it at the opening bell on Monday.
Netflix has barely begun to meet its social media potential.
Despite its success in places like China and Russia, Ford is fast falling behind in India. Here's what Ford is doing to hang on in this huge emerging market.
What tripped up Boston Beer this earnings season?
A quick look at whether investors should be buying, selling, or holding shares of Microsoft now that it is up more than 30% year-to-date.
This stocks yield may not be a jaw-dropper yet, but it's positioned "purrrrrfectly" in a rapidly growing sector to deliver long term profits and payouts.
General Motors has had a presence in Brazil for ages, but lately, its position in this fast-growing market has come under pressure. Here's how GM plans to respond.
Distortions in this widely cited metric, make it practically useless for investors.
This Fool sees a limb to go out on.
The cable network doesn’t need to spin-off HBO GO to profit.
These deadly diseases kill more than 1 million Americans every year. But there's still some good news.
General Motors' Australian operation is losing money, thanks to cheap imports. Sound familiar? Here's what GM is doing about it.
Biogen's MS drug is off to a hot start, and its new hemophilia drugs are under FDA review.
You know it's big. You know it's growing. Now we'll tell you how to profit from it.
Once left for dead, this industry has been making a comeback.
Carl Icahn wants to give Dell stock owners $12 each. However, his plan may unravel if he convinces too many people that the company is massively undervalued.